FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035367987> ?p ?o ?g. }

• W3035367987 abstract "Insulin icodec* (icodec) is a novel basal insulin analog with a terminal half-life of ∼196 hours in development as the first once-weekly insulin. This 26-week, randomized, double-blind, double-dummy, treat-to-target, phase 2 trial investigated the efficacy and safety of once-weekly icodec vs. once-daily insulin glargine U100 (IGlar U100) in insulin-naïve patients with T2D inadequately controlled (A1C 7.0-9.5%) with metformin ± DPP-4i. Starting doses were 70 U weekly and 10 U daily, respectively, with weekly titration to a pre-breakfast SMBG target of 70-108 mg/dL. Primary endpoint was change in A1C from baseline to week 26. Secondary endpoints included change in FPG from baseline to week 26 and hypoglycemic episodes. Participants (n = 247) were randomized 1:1 to icodec (n = 125) or IGlar U100 (n = 122). Baseline characteristics appeared similar in both groups; mean age was 59.6 years, diabetes duration 9.7 years, BMI 31.3 kg/m2 and FPG 181 mg/dL. Mean baseline A1C was 8.1% (icodec) and 8.0% (IGlar U100). At week 26, estimated mean A1C was 6.69% for icodec and 6.87% for IGlar U100 (estimated mean change from baseline: -1.33% and -1.15%-points, respectively). There was no statistically significant treatment difference for change in A1C from baseline to week 26 (-0.18%, 95% CI, -0.38; 0.02). Estimated mean FPG at week 26 was 123 mg/dL (icodec) and 127 mg/dL (IGlar U100). Observed rates of level 2 (&lt;54 mg/dL) + 3 (severe) hypoglycemia were low (60.55 and 52.36 events per 100 patient years of exposure for icodec and IGlar U100, respectively) and were comparable (p = 0.85). There were no unexpected safety findings. In conclusion, icodec is the first once-weekly insulin with similar glucose-lowering effects and safety profile to once-daily IGlar U100. Icodec could improve treatment acceptance and facilitate T2D management in patients needing basal insulin. *Proposed INN. Disclosure J. Rosenstock: None. M.I.S. Kjaersgaard: Employee; Self; Novo Nordisk A/S. D. Moller: Employee; Self; Novo Nordisk A/S. M. Voigt Hansen: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. R. Goldenberg: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk Inc., Sanofi." @default.
• W3035367987 created "2020-06-19" @default.
• W3035367987 creator A5011703939 @default.
• W3035367987 creator A5026176656 @default.
• W3035367987 creator A5027019744 @default.
• W3035367987 creator A5045328872 @default.
• W3035367987 creator A5045489578 @default.
• W3035367987 date "2020-06-01" @default.
• W3035367987 modified "2023-09-26" @default.
• W3035367987 title "238-OR: Once-Weekly Basal Insulin Icodec Offers Comparable Efficacy and Safety vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve Patients with T2D Inadequately Controlled on OADS" @default.
• W3035367987 doi "https://doi.org/10.2337/db20-238-or" @default.
• W3035367987 hasPublicationYear "2020" @default.
• W3035367987 type Work @default.
• W3035367987 sameAs 3035367987 @default.
• W3035367987 citedByCount "2" @default.
• W3035367987 countsByYear W30353679872021 @default.
• W3035367987 crossrefType "journal-article" @default.
• W3035367987 hasAuthorship W3035367987A5011703939 @default.
• W3035367987 hasAuthorship W3035367987A5026176656 @default.
• W3035367987 hasAuthorship W3035367987A5027019744 @default.
• W3035367987 hasAuthorship W3035367987A5045328872 @default.
• W3035367987 hasAuthorship W3035367987A5045489578 @default.
• W3035367987 hasConcept C126322002 @default.
• W3035367987 hasConcept C134018914 @default.
• W3035367987 hasConcept C2778024521 @default.
• W3035367987 hasConcept C2779306644 @default.
• W3035367987 hasConcept C2779920387 @default.
• W3035367987 hasConcept C2780668416 @default.
• W3035367987 hasConcept C555293320 @default.
• W3035367987 hasConcept C71924100 @default.
• W3035367987 hasConceptScore W3035367987C126322002 @default.
• W3035367987 hasConceptScore W3035367987C134018914 @default.
• W3035367987 hasConceptScore W3035367987C2778024521 @default.
• W3035367987 hasConceptScore W3035367987C2779306644 @default.
• W3035367987 hasConceptScore W3035367987C2779920387 @default.
• W3035367987 hasConceptScore W3035367987C2780668416 @default.
• W3035367987 hasConceptScore W3035367987C555293320 @default.
• W3035367987 hasConceptScore W3035367987C71924100 @default.
• W3035367987 hasIssue "Supplement_1" @default.
• W3035367987 hasLocation W30353679871 @default.
• W3035367987 hasOpenAccess W3035367987 @default.
• W3035367987 hasPrimaryLocation W30353679871 @default.
• W3035367987 hasRelatedWork W1966225706 @default.
• W3035367987 hasRelatedWork W1974106130 @default.
• W3035367987 hasRelatedWork W2016328345 @default.
• W3035367987 hasRelatedWork W2042819106 @default.
• W3035367987 hasRelatedWork W2048226041 @default.
• W3035367987 hasRelatedWork W2066345847 @default.
• W3035367987 hasRelatedWork W2068166803 @default.
• W3035367987 hasRelatedWork W2166209517 @default.
• W3035367987 hasRelatedWork W2171960002 @default.
• W3035367987 hasRelatedWork W2430205611 @default.
• W3035367987 hasVolume "69" @default.
• W3035367987 isParatext "false" @default.
• W3035367987 isRetracted "false" @default.
• W3035367987 magId "3035367987" @default.
• W3035367987 workType "article" @default.